在全球肿瘤治疗进入精准医疗时代的背景下，个性化免疫疗法成为突破传统治疗瓶颈的核心方向。立康生命科技成立于2017年，扎根北京经济技术开发区， 是一家专注于个性化肿瘤疫苗和T细胞药物研发的创新型生物医药企业。作为国家高新技术企业、北京市"专精特新"企业，公司以"开发First in Class的免疫 细胞药物"为宗旨，汇聚国内外顶尖科研与产业人才，研发人员占比高达84%，凭借自主知识产权的核心技术平台，在肿瘤精准免疫治疗领域持续突破，先 后入围德勤中国医药健康明日之星、毕马威生物科创领航50等权威榜单。 陈贝倪/文 免责声明：本文观点仅代表作者本人，供参考、交流，不构成任何建议。 收藏 著提升了安全性与耐受性。其核心技术依托肿瘤新抗原分析生物信息学平台（LNEA）、高通量抗原/T细胞筛选平台，结合AI技术实现个性化靶点精准筛 选，形成全链路技术闭环。 自研发以来，LK101注射液已取得一系列突破性成果。在监管批准方面，产品于2023年3月获得国家药品监督管理局（NMPA）首款AI+个性化靶点mRNA肿 瘤疫苗IND临床批件；2025年2月获美国食品药品管理局（FDA）IND批准，成为中国首款且目前唯一获FDA批 ...

Core Insights - The mRNA industry is transitioning from a pandemic-driven boom to a critical transformation phase, with significant potential in cancer immunotherapy and personalized medicine [1][6][7] - Major players like BioNTech and Moderna are adjusting their strategies in response to declining revenues from COVID-19 vaccines, focusing on expanding their cancer treatment pipelines [6][7] Industry Developments - mRNA technology has shown promise in various applications beyond vaccines, including therapeutic vaccines, cancer immunotherapy, and regenerative medicine [4][5] - The market potential for mRNA cancer vaccines is projected to reach hundreds of billions of dollars, driven by their accessibility and personalization capabilities [1][4] Company Strategies - BioNTech has made strategic acquisitions to enhance its capabilities in mRNA cancer immunotherapy, including a $1.25 billion acquisition of CureVac [1] - Moderna is facing financial challenges, with a projected revenue drop of 33% in 2025, leading to workforce reductions [6][7] Market Dynamics - The Chinese mRNA sector is experiencing a bifurcation, with some companies like Simao Biotechnology facing financial difficulties, while others are making significant advancements [8][9] - Chinese companies are gaining international recognition, with successful FDA approvals for innovative mRNA cancer vaccines [9] Future Outlook - The mRNA industry is expected to evolve towards a model where drug development is based on "coding nucleic acid sequences," potentially revolutionizing treatment for various diseases [5][10] - The success of Chinese mRNA companies in the competitive landscape will depend on their ability to leverage business development opportunities for rapid monetization [10]